PSTV Form 4 — Andrew Sims reports 38,323 RSU vesting

Rhea-AI Filing Summary

Andrew John Hugh MacIntyre Sims, listed as Chief Financial Officer and Director of Plus Therapeutics, Inc. (PSTV), filed a Form 4 disclosing insider changes effective 10/01/2025. The filing reports the vesting of 38,323 Restricted Stock Units (RSUs) that are each a contingent right to one share, recorded with a transaction code M and a reported price of $0. After the reported transaction the filing shows 48,138 shares of Common Stock beneficially owned directly and 421,555 derivative securities (RSUs) reported as beneficially owned following the transaction. The filing states these RSUs vest in twelve substantially equal quarterly installments beginning on 10/01/2025.

Positive

• 38,323 RSUs vested to the reporting person, increasing immediate share ownership
• Vesting schedule disclosed: RSUs vest in 12 substantially equal quarterly installments beginning 10/01/2025, showing a predictable compensation timeline

Negative

• None.

Insights

Corporate Insider / Compensation Analyst

Insider vested 38,323 RSUs; ongoing multi-quarter vesting schedule disclosed.

The Form 4 shows an insider vesting event recorded under transaction code M on 10/01/2025, representing the conversion of 38,323 RSUs into common shares at a reported price of $0. The filing also reports remaining derivative holdings of 421,555 RSUs and direct ownership of 48,138 shares after the transaction.

This matters because the filing documents a scheduled compensation vesting rather than an open-market purchase or sale; the disclosed RSU tranche is part of a planned, time-based vesting that will occur in twelve substantially equal quarterly installments beginning 10/01/2025.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Sims Andrew John Hugh MacIntyre

(Last) (First) (Middle)

C/O PLUS THERAPEUTICS INC.

4200 MARATHON BOULEVARD, SUITE 200

(Street)

AUSTIN TX 78756

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
PLUS THERAPEUTICS, INC. [ PSTV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
10/01/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/01/2025		M		38,323(2)	A	$0(1)	48,138	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	$0	10/01/2025		M			38,323	(2)	(2)	Common Stock	38,323	$0	421,555	D

Explanation of Responses:

1. Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the issuer's Common Stock.

2. Represents the vesting of an RSU grant which occurs in twelve substantially equal quarterly installments beginning on October 1, 2025.

	/s/ Andrew Sims	10/03/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Plus Therapeutics (PSTV) disclose in this Form 4?

The Form 4 discloses that CFO Andrew Sims had 38,323 RSUs vest on 10/01/2025 and reports post-transaction beneficial ownership of 48,138 common shares and 421,555 RSUs.

How are the RSUs described in the filing structured?

Each Restricted Stock Unit is described as a contingent right to receive one share of the issuer's common stock, with vesting in 12 substantially equal quarterly installments beginning 10/01/2025.

What transaction code was used and what does it indicate?

The filing lists transaction code M, indicating a transaction such as the conversion/vesting of derivative securities into shares as reported on the Form 4.

What amount of securities does the reporting person own after the transaction?

The Form 4 reports 48,138 shares of Common Stock and 421,555 derivative securities (RSUs) beneficially owned following the reported transaction.

When was the Form 4 signed?

The Form 4 was signed by Andrew Sims on 10/03/2025.